
|Articles|January 1, 2004
FDA approves first accommodative IOL
Cataract surgeons who participated in the premarketing clinical trials for the model AT-45 accommodative IOL (Crystalens, eyeonics inc. [formerly C&C Vision]) are heralding that technology as an important advance. The lens affords patients clear uncorrected vision at near, intermediate, and distance. FDA approval for marketing of the lens was granted in November.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
2
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
3
Recognizing biomarkers of Alzheimer Disease using OCTA
4
Midyear cataract check-in: What 2026 has brought to the OR and beyond
5





















